Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions

被引：46
|
作者：
Schweighardt, B [1 ]
Ortiz, GM
Grant, RM
Wellons, M
Miralles, GD
Kostrikis, LG
Bartlett, JA
Nixon, DF
机构：
[1] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA
[2] Duke Univ, Med Ctr, Ctr AIDS Res, Durham, NC USA
[3] Trimeris Pharmaceut, Durham, NC USA
[4] Univ Athens, Sch Med, GR-11527 Athens, Greece
来源：
AIDS | 2002年 / 16卷 / 17期
关键词：
D O I：
10.1097/00002030-200211220-00018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the emergence of drug-resistant viral mutations in chronically HIV-infected individuals undergoing structured treatment interruptions (STI). The protease mutation M46L and the reverse transcriptase mutations K101E and K103N were detected at the end of the second or third STI. We conclude that the repeated abrupt termination and resumption of certain antiretroviral drug regimens during STI therapy may lead to the development of drug resistance in chronically HIV-infected individuals.
引用
收藏
页码：2342 / 2344
页数：3
相关论文
共 50 条
  • [41] Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection
    Bonhoeffer, S
    Rembiszewski, M
    Ortiz, GM
    Nixon, DF
    AIDS, 2000, 14 (15) : 2313 - 2322
  • [42] Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Lazzarin, A
    Clotet, B
    Cooper, D
    Reynes, J
    Arasteh, K
    Nelson, M
    Katlama, C
    Stellbrink, H
    Delfraissy, J
    Lange, J
    Huson, L
    DeMasi, R
    Wat, C
    Delehanty, J
    Drobnes, C
    Salgo, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (22): : 2186 - 2195
  • [43] A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions:: a randomized study
    García, F
    Plana, M
    Arnedo, M
    Ortiz, GA
    Miró, JA
    Lopalco, L
    Lori, F
    Pumarola, T
    Gallart, T
    Gatell, JM
    AIDS, 2003, 17 (01) : 43 - 51
  • [44] Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
    Frenkel, LM
    Mullins, JI
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07): : 520 - 522
  • [45] Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients
    Papasavvas, E
    Grant, RM
    Sun, JW
    Mackiewicz, A
    Pistilli, M
    Gallo, G
    Kostman, JR
    Mounzer, K
    Shull, J
    Montaner, LJ
    AIDS, 2003, 17 (16) : 2337 - 2343
  • [46] Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads
    Tuldrà, A
    Fumaz, CR
    Ferrer, MJ
    Paredes, R
    Romeu, J
    Ruiz, L
    Bayés, R
    Clotet, B
    AIDS, 2001, 15 (14) : 1904 - 1906
  • [47] Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
    Kambili, C.
    Rossenu, S.
    Hoetelmans, R. M. W.
    Birmingham, E.
    Bakare, N.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (07) : 671 - 677
  • [48] Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan
    Hattori, Junko
    Shiino, Teiichiro
    Gatanaga, Hiroyuki
    Mori, Haruyo
    Minami, Rumi
    Uchida, Kazue
    Sadamasu, Kenji
    Kondo, Makiko
    Sugiura, Wataru
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (04) : 367 - 373
  • [49] Drug resistance: crystallography of drug-resistant HIV-1 protease mutant
    Raskar, Tushar
    Das, Amit
    Hosur, M. V.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2015, 33 : 124 - 124
  • [50] Distribution of drug-resistant HIV-1 variants in plasma RNA and peripheral blood monuclear cell DNA in patients on therapy and after treatment interruption
    Romano, L
    Venturi, G
    Carli, T
    Corsi, P
    Pippi, L
    Valensin, PE
    Zazzi, M
    ANTIVIRAL THERAPY, 2002, 7 : S122 - S122
12345